Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

By G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, J. Tanguay, J. T. ten Berg, Debra L. Miller, T. Costigan, J. Goedicke and 10 more. New England Journal of Medicine, 2013

613 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/6d2d6f3a3bdf571c79bb3b07913f31788282ae6b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jose Luis Zamorano
2. Hani Jneid
3. Allan S. Jaffe
4. Stephan Windecker

Citations in the corpus

• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “The ACCOAST (A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients With Non–ST-Elevation Myocardial Infarction) RCT of high-risk patients with NSTEACS scheduled to undergo early coronary angiography found that a strategy o”
• 2018 ESC/EACTS Guidelines on myocardial revascularization. (2019, neutral): “Administration of prasugrel in patients in whom coronary anatomy is not known is not recommended.(165) III B”
• [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, methodology): “Pre-treatment did not reduce the rate of the primary outcome among patients undergoing PCI (69% of the patients) but increased the rate of TIMI major bleeding at 7 days [25].”